Triprolidine


Concise Prescribing Info
Indications/Uses
Allergic conditions.
Dosage/Direction for Use
Adult : PO 2.5 mg 4-6 hrly. Max: 10 mg/day.
Dosage Details
Oral
Allergic conditions
Adult: 2.5 mg 4-6 hrly. Max: 10 mg daily.
Child: 4 mth to <2 yr 0.313 mg 4-6 hrly. Max: 1.252 mg daily; 2-<4 yr 0.625 mg 4-6 hrly. Max: 2.5 mg daily; 4-<6 yr 0.938 mg 4-6 hrly. Max: 3.744 mg daily; 6-<12 yr 1.25 mg 4-6 hrly. Max: 5 mg daily; ≥12 yr Same as adult dose.
Administration
May be taken with or without food.
Special Precautions
Patient w/ angle-closure glaucoma, prostatic hypertrophy, pyloroduodenal obstruction, stenosing peptic ulcer, bladder or neck obstruction.
Adverse Reactions
Excitability (esp in childn), sedation, dizziness, lassitude, disturbed coordination, muscular weakness, anorexia, nausea, vomiting, diarrhoea, epigastric distress, tachycardia, ECG changes, arrhythmias, dry mouth, urinary retention, impotence, vertigo, visual disturbances, blurred vision, diplopia, tinnitus, acute labyrinthitis, irritability, facial dyskinesia, wheezing, nasal stuffiness, sweating, chills, headache, faintness, paraesthesia. Rarely, leucopenia, thrombocytopenia, haemolytic anaemia.
Patient Counseling Information
This drug may cause dizziness, drowsiness or weakness, if affected, do not drive or operate machinery.
Drug Interactions
Increased sedation w/ CNS depressants (e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics, sedatives and antipsychotics). Increased antimuscarinic side effects w/ other antimuscarinic drugs (e.g. atropine, TCA and MAOI). May mask signs of ototoxicity caused by aminoglycosides.
Food Interaction
Increased sedation w/ alcohol.
Action
Description: Triprolidine blocks the action of endogenous histamine by binding to H1 receptor. It is useful for the prevention and suppression of the signs and symptoms of allergic rhinitis and other upper resp allergies.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: Approx 2 hr.
Distribution: Distributed into breast milk.
Metabolism: Metabolised hepatically to carboxylated derivative.
Excretion: Via urine, approx 1% as unchanged drug. Elimination half-life: Approx 2 hr.
Chemical Structure

Chemical Structure Image
Triprolidine

Source: National Center for Biotechnology Information. PubChem Database. Triprolidine, CID=5282443, https://pubchem.ncbi.nlm.nih.gov/compound/Triprolidine (accessed on Jan. 23, 2020)

Storage
Store between 15-30°C.
ATC Classification
R06AX07 - triprolidine ; Belongs to the class of other antihistamines for systemic use.
References
Anon. Triprolidine Hydrochloride. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 11/07/2016.

Anon. Triprolidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/07/2016.

Buckingham R (ed). Interactions of Antihistamines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/07/2016.

Buckingham R (ed). Triprolidine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/07/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Antihistamines General Statement. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 12/07/2016.

Vanahist PD Liquid (GM Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 21/04/2014.

Disclaimer: This information is independently developed by MIMS based on Triprolidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in